Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia Proceeds Expected to Fund Ongoing Development and ...
Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company’s First and Next Generation Proprietary Ultralow Cryoablation Technologies LAGUNA HILLS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback